<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209219</url>
  </required_header>
  <id_info>
    <org_study_id>Z171100001017217</org_study_id>
    <nct_id>NCT03209219</nct_id>
  </id_info>
  <brief_title>Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis</brief_title>
  <official_title>Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a&#xD;
      and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral&#xD;
      glucocorticosteroid in patients with refractory Behçet's uveitis (BDU). Half of the&#xD;
      participants will receive IFNα2a while the other half will receive CsA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description: Both CsA and IFNα2a have been shown to be effective for long-term&#xD;
      control of BDU, however, randomized prospective comparative studies are scarce, particularly&#xD;
      in East Asian populations. Our preliminary data gave us the impression that IFNα2a might be&#xD;
      more effectiveness than CsA in long-term control of refractory BDU, and this study aimed to&#xD;
      compare their effectiveness and safety profiles in a well-designed prospective study.&#xD;
      Refractory BDU is defined as relapse of posterior or pan- uveitis with at least 10mg daily&#xD;
      prednisone (or equivalent) and one traditional immunomodulatory treatment (IMT) agents. The&#xD;
      acute attack is controlled with large dose oral corticosteroid (60mg daily prednisone) for 4&#xD;
      weeks, and then the patients are randomly assigned to the IFN arm and the CsA arm, in which&#xD;
      patients are treated with IFNα2a (3×10^6 IU qd for 4 weeks and qod thereafter) and CsA (100mg&#xD;
      bid), respectively, along with a fixed tapering regimen of corticosteroid. Patients were&#xD;
      followed up until relapse, or for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Percentage of participants who achieve complete remission or partial remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Percentage of participants who achieve complete remission without relapse of posterior or pan-uveitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance rate</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Percentage of participants who adhere to the treatment without severe side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach complete remission</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>The time from the therapy initiation to a complete absence of ocular inflammation for complete responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of relapse-free</measure>
    <time_frame>within the 12-month follow-up period</time_frame>
    <description>The duration between the therapy initiation to the relapse for partial responders and nonresponders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Changes of best-corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOS24 score</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Score of ocular inflammation using the Behcet disease ocular attack score 24 (BOS24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid-sparing effect</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Changes of corticosteroid dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Incidence of adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of significant abnormal changes in vital signs or laboratory test results</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Incidence of significant abnormal changes in vital signs or laboratory test results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects profile</measure>
    <time_frame>Within the 12-month follow-up period</time_frame>
    <description>Types of drug adverse effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Behçet Disease</condition>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Interferon Alpha 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with oral CsA 100mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa-2A</intervention_name>
    <description>3×10^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter</description>
    <arm_group_label>Interferon Alpha 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Pill</intervention_name>
    <description>100mg， oral, bid</description>
    <arm_group_label>Cyclosporine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory BDU patients fulfilling the International Criteria for Behçet's disease&#xD;
             (ICBD) published in 2013 with recent recurrence of pan- or posterior uveitis;&#xD;
&#xD;
          -  The patient should be on ≥10mg/d oral prednisone or equivalent with at least one of&#xD;
             the following IMT agents: cyclophosphamide≥50mg/d, CsA≥100mg/d, azathioprine≥50mg/d,&#xD;
             methotrexate≥15mg/w, mycophenolate≥1000mg/d, tacrolimus≥2mg/d.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with interferon-α;&#xD;
&#xD;
          -  Pregnancy, breast feeding women;&#xD;
&#xD;
          -  Malignancy;&#xD;
&#xD;
          -  Renal impairment (creatinine &gt; 1.5 mg/dl);&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes;&#xD;
&#xD;
          -  Depression or other psychic disorders;&#xD;
&#xD;
          -  History of acute or chronic inflammatory joint or autoimmune disease;&#xD;
&#xD;
          -  Patients with severe extra-ocular involvement other than oral/genital ulcer and skin&#xD;
             involvement;&#xD;
&#xD;
          -  Organ or bone marrow transplant recipient, cardiac failure &gt; NYHA III;&#xD;
&#xD;
          -  Acute liver disease with ALT or SGPT 2x above normal;&#xD;
&#xD;
          -  White blood cell count &lt; 3500/mm^3;&#xD;
&#xD;
          -  Platelet count &lt; 100000/mm^3;&#xD;
&#xD;
          -  Hgb &lt; 8.5g/dl;&#xD;
&#xD;
          -  T-SPOT TB: ≥200 SFCs per 10^6 PBMC;&#xD;
&#xD;
          -  Active peptic ulcer, systemic or local infection, moderate to severe osteoporosis or&#xD;
             other contraindications of large dose corticosteroids;&#xD;
&#xD;
          -  Previous intolerance to CsA;&#xD;
&#xD;
          -  Other severe ocular diseases or intraocular surgery within 3 months;&#xD;
&#xD;
          -  Media opacity precluding a clear view of the fundus;&#xD;
&#xD;
          -  Positive screen test for HBV, HCV, HIV infection or syphilis;&#xD;
&#xD;
          -  Body weight &lt;45 kg;&#xD;
&#xD;
          -  Alcohol abuse or drug abuse;&#xD;
&#xD;
          -  Mental impairment;&#xD;
&#xD;
          -  Uncooperative attitude.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Meifen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>effectiveness, safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual participant data are available from the investigator upon reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

